Anti-Hu CD14 PE-DyLight® 594

Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Dry Ice Shipment: No

Alternative Products

Cat	Name
MBS1801044-01	Anti-Hu CD14 PE-DyLight 594
MBS1801044-02	Anti-Hu CD14 PE-DyLight 594
MBS1801084-01	Anti-Hu CD14 PE
MBS1801084-02	Anti-Hu CD14 PE
MBS1801041-01	Anti-Hu CD14 PE
MBS1801041-02	Anti-Hu CD14 PE
MBS1801046-01	Anti-Hu CD14 PE-Cyanine5
MBS1801045-01	Anti-Hu CD14 PE-Cyanine7
MBS1801045-02	Anti-Hu CD14 PE-Cyanine7
MBS1801046-02	Anti-Hu CD14 PE-Cyanine5

CAT:

270-T5-293-T025

Size:

25 Tests

Price:

Ask

For price, please contact [email protected].

Anti-Hu CD14 PE-DyLight® 594

Clone: MEM-15
Format: PE-DyLight® 594
Buffer: Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
References & Citations: *Majer F, Vlaskova H, Krol L, Kalina T, Kubanek M, Stolnaya L, Dvorakova L, Elleder M, Sikora J: Danon disease: a focus on processing of the novel LAMP2 mutation and comments on the beneficial use of peripheral white blood cells in the diagnosis of LAMP2 deficiency. Gene. 2012 May 1498(2):183-95., URL: https://pubmed.ncbi.nlm.nih.gov/22365987/,*Kanderova V, Kuzilkova D, Stuchly J, Vaskova M, Brdicka T, Fiser K, Hrusak O, Lund-Johansen F, Kalina T: High-resolution Antibody Array Analysis of Childhood Acute Leukemia Cells. Mol Cell Proteomics. 2016 Apr15(4):1246-61., URL: http://www.ncbi.nlm.nih.gov/pubmed/26785729 ,*Jeraiby M, Sidi Yahya K, Depince-Berger AE, Lambert C: Microbicidal activity measured by flow cytometry: Optimization and standardization for detection of primary and functional deficiencies. J Immunol Methods. 2016 Sep 29. pii: S0022-1759(16)30220-4., URL: https://www.ncbi.nlm.nih.gov/pubmed/27693641 ,*Sing A, Rost D, Tvardovskaia N, Roggenkamp A, Wiedemann A, Kirschning CJ, Aepfelbacher M, Heesemann J: Yersinia V-antigen exploits toll-like receptor 2 and CD14 for interleukin 10-mediated immunosuppression. J Exp Med. 2002 Oct 21196(8):1017-24., URL: http://www.ncbi.nlm.nih.gov/pubmed/12391013 ,*Schiff DE, Rae J, Martin TR, Davis BH, Curnutte JT: Increased phagocyte Fc gammaRI expression and improved Fc gamma-receptor-mediated phagocytosis after in vivo recombinant human interferon-gamma treatment of normal human subjects. Blood. 1997 Oct 1590(8):3187-94., URL: http://www.ncbi.nlm.nih.gov/pubmed/9376602 ,*Leukocyte Typing VI., Kishimoto T. et al. (Eds.), Garland Publishing Inc. (1997)., URL: ,*Leukocyte Typing V., Schlossman S. et al. (Eds.), Oxford University Press (1995)., URL: ,*Leukocyte Typing IV., Knapp W. et al. (Eds.), Oxford University Press (1989)., URL: ,*Leukocyte Typing III., McMichael A. J. et al (Eds.), Oxford University Press (1987)., URL: ,*Bazil V, Horejsi V, Baudys M, Kristofova H, Strominger JL, Kostka W, Hilgert I: Biochemical characterization of a soluble form of the 53-kDa monocyte surface antigen. Eur J Immunol. 1986 Dec16(12):1583-9., URL: https://www.ncbi.nlm.nih.gov/pubmed/3493149?dopt=A,*Funda DP, Tucková L, Farré MA, Iwase T, Moro I, Tlaskalová-Hogenová H: CD14 is expressed and released as soluble CD14 by human intestinal epithelial cells in vitro: lipopolysaccharide activation of epithelial cells revisited. Infect Immun. 2001 Jun69(6):3772-81., URL: http://www.ncbi.nlm.nih.gov/pubmed/11349042 ,*Cejkova P, Nemeckova I, Broz J, Cerna M: TLR2 and TLR4 expression on CD14++ and CD14+ monocyte subtypes in adult-onset autoimmune diabetes. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015 May 4. doi: 10.5507/bp.2015.016., URL: http://www.ncbi.nlm.nih.gov/pubmed/?term=cejkova+p+nemeckova+i+broz+j+cerna+m ,
Other References: *Juan TS, Hailman E, Kelley MJ, Wright SD, Lichenstein HS: Identification of a domain in soluble CD14 essential for lipopolysaccharide (LPS) signaling but not LPS binding. J Biol Chem. 1995 Jul 21270(29):17237-42., URL: https://pubmed.ncbi.nlm.nih.gov/7542233/,*Lodrup Carlsen KC, Granum B: Soluble CD14: role in atopic disease and recurrent infections, including otitis media. Curr Allergy Asthma Rep. 2007 Nov7(6):436-43., URL: https://pubmed.ncbi.nlm.nih.gov/17986374/,*Asai Y, Makimura Y, Kawabata A, Ogawa T: Soluble CD14 discriminates slight structural differences between lipid as that lead to distinct host cell activation. J Immunol. 2007 Dec 1179(11):7674-83., URL: https://pubmed.ncbi.nlm.nih.gov/18025213/,*Fernández-Real JM, Broch M, Richart C, Vendrell J, López-Bermejo A, Ricart W: CD14 monocyte receptor, involved in the inflammatory cascade, and insulin sensitivity. J Clin Endocrinol Metab. 2003 Apr88(4):1780-4., URL: https://pubmed.ncbi.nlm.nih.gov/12679473/,

Complementary Product Range

Our range of products, including Anti-Hu CD14 PE-DyLight® 594, falls within the same field of application and can be used across various research projects. These products are carefully selected for their high performance and reliability, supporting the diverse needs of modern laboratories. Whether for ongoing studies or future experiments, they are designed to help researchers achieve their scientific goals. Here are some related products that may be of interest for similar or future applications:

Each item in our collection, is tested for precision and quality, ensuring dependable solutions for your research. As we continue to incorporate the latest advancements, Gentaur ensures that our product range remains relevant and versatile, providing you with the tools needed for both current and future projects.

Find us on

Cat	Name
T5-293-T025	Anti-Hu CD14 PE-DyLight® 594
T5-293-T100	Anti-Hu CD14 PE-DyLight® 594
T5-206-T025	Anti-Hu CD7 PE-DyLight® 594
T5-207-T100	Anti-Hu CD8 PE-DyLight® 594
T5-222-T025	Anti-Hu CD45 PE-DyLight® 594
T5-223-T025	Anti-Hu CD45RA PE-DyLight® 594
T5-297-T100	Anti-Hu CD34 PE-DyLight® 594
T5-305-T100	Anti-Hu CD19 PE-DyLight® 594
T5-359-T025	Anti-Hu CD4 PE-DyLight® 594
T5-366-T025	Anti-Hu CD38 PE-DyLight® 594